Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180809

SCHEMBL7180809

SCHEMBL7180809

COc1cccc(OC)c1C(=O)[P](=O)c1ccccc1C(=O)c1c(Cl)c(Cl)cc(Cl)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ BCL2L11 O43521 1/20 0.38
▸ BCL2L1 Q07817 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ MAPK13 O15264 1/20 0.37
▸ MAPK12 P53778 1/20 0.37
▸ MAPK11 Q15759 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ KMT2A Q03164 3/20 0.36
▸ CES2 O00748 1/20 0.36
▸ CES1 P23141 1/20 0.36
▸ KCNK3 O14649 1/20 0.36
▸ KCNK9 Q9NPC2 1/20 0.36
▸ RORC P51449 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7178126 0.92 KMT2A (0.41) LMNABCL2L11BCL2L1MCL1MAPK13
SCHEMBL7189134 0.91 CA12 (0.40) LMNABCL2L11BCL2L1MCL1MAPK13
SCHEMBL7174638 0.91 HPGD (0.38) LMNABCL2L11BCL2L1MCL1MAPK13
SCHEMBL7186470 0.89 RORC (0.42) LMNABCL2L11BCL2L1MCL1MAPK13
SCHEMBL7177554 0.88 LMNA (0.39) LMNABCL2L11BCL2L1MCL1MAPK13
SCHEMBL7180955 0.85 RECQL (0.36) LMNACES2CES1RORCRORB
SCHEMBL7182505 0.84 KMT2A (0.40) LMNAKMT2ARAB9ASMN1; SMN2HPGD
SCHEMBL7188977 0.84 MAPT (0.41) CA12CA1CA2CA7CA9
SCHEMBL7182191 0.84 MAPK13 (0.37) LMNAMAPK13MAPK12MAPK11MAPK14
SCHEMBL7180936 0.84 KMT2A (0.40) LMNABCL2L11BCL2L1MCL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885BCL2L11 172/4885BCL2L1 1400/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885BCL2L11 186/4885BCL2L1 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.